Considering the patient's clinical features, which include immunosuppression due to anti-TNF therapy, the absence of a personal history of TB, a positive IGRA result (despite prior BCG vaccination, which may influence the outcome), and the occupational exposure risk linked to her profession, a decision was made to commence empirical treatment and monitor the response to therapy. This evidence concerns the gene TNF and tuberculosis.